Roche: Oddo still a buyer after acquisition of Flatiron
(CercleFinance.com) - Last night Roche announced the acquisition of the US private company Flatiron Health, which is based in New York, for 1.
9 billion dollars. Following this announcement, Oddo confirmed its buy rating on the stock, maintaining its target price at 272 Swiss francs.
Oddo said that Flatiron is a strategic acquisition for Roche, which it could afford to pay close to 2 billion for: as such, the acquisition is not changing its estimates. We expect 2018 revenues of 55.2 billion Swiss francs, with Core EPS of 16.74 Swiss francs (Factset consensus expects EPS of 16.26 Swiss francs).
Flatiron is a technology & services company that is specialised in software enabling electronic data recording in oncology (patients, treatment, research, real-world evidence, etc.).
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
9 billion dollars. Following this announcement, Oddo confirmed its buy rating on the stock, maintaining its target price at 272 Swiss francs.
Oddo said that Flatiron is a strategic acquisition for Roche, which it could afford to pay close to 2 billion for: as such, the acquisition is not changing its estimates. We expect 2018 revenues of 55.2 billion Swiss francs, with Core EPS of 16.74 Swiss francs (Factset consensus expects EPS of 16.26 Swiss francs).
Flatiron is a technology & services company that is specialised in software enabling electronic data recording in oncology (patients, treatment, research, real-world evidence, etc.).
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.